Trump's 25% tariff rattles Nifty futures. How bad is the news for Indian stock market?
Gift Nifty
plunged nearly 170 points after the announcement.
Trump accused India of maintaining some of the "most strenuous and obnoxious non-monetary trade barriers" and of running a "massive" trade surplus with the US.
Explore courses from Top Institutes in
Please select course:
Select a Course Category
Cybersecurity
CXO
MBA
Finance
Data Analytics
Project Management
Technology
Artificial Intelligence
Product Management
Operations Management
Digital Marketing
Degree
MCA
Public Policy
Data Science
Leadership
healthcare
Healthcare
Others
others
Design Thinking
Management
PGDM
Data Science
Skills you'll gain:
Duration:
10 Months
MIT xPRO
CERT-MIT xPRO PGC in Cybersecurity
Starts on
undefined
Get Details
The decision has sent the rupee tumbling, posting its steepest one-day drop since May and hit a five-month low on Wednesday.
What US tariff means for Indian markets
Nilesh Shah, MD at Kotak Mahindra AMC, called the tariff move a clear negative for the markets. 'Despite unpredictable US policy moves, markets were expecting a tariff deal to eventually work out because long-term US-India strategic interests are aligned,' he said.
He hopes that cooler heads will prevail and that a 'TACO' (Trade Agreement on Competitive Offerings) deal could still materialize if both sides reassess their red lines.
However, Shah also issued a cautionary note, urging India to take this moment to accelerate internal reforms that enhance competitiveness.
"Our biggest deterrence continues to be our GDP size and productivity. China is defying US pressure because of scale and competitiveness. India must learn from that."
India and the US had opened wide-ranging trade talks earlier this year, with hopes that a deal could be signed by mid-2025. However, disagreements over market access, especially in agriculture and dairy, stalled negotiations.
Trump has often used tariffs as a blunt instrument to force compliance -- a playbook he appears to be returning to with renewed fervor. Should he tighten the screws further, India may be forced to recalibrate its trade strategy not only with the US, but globally.
According to Garima Kapoor, EVP at Elara Capital, the new tariff puts India at a disadvantage against export competitors like Vietnam, Indonesia and the Philippines, which continue to enjoy lower tariff rates into the US market.
If pharmaceuticals are included in the tariff ambit, the damage could be significant. The US accounts for over 30% of India's pharma exports, making it a key pillar of India's outward trade.
The lack of clarity on whether pharma and high-value goods like auto components and steel will be taxed uniformly is adding to the market's unease.
Kapoor warns that if a trade deal is not reached by September or October, India's full-year GDP growth could see a downward revision of at least 20 basis points. However, she notes that the delay might be a blessing in disguise.
'A hotchpotch deal that gave away too much on agriculture and dairy could have had far-reaching political and social costs. A well-negotiated deal, even if delayed, is preferable,' she said.
"The tariff (and penalty) now proposed by the US is higher than what we had anticipated, and is therefore likely to pose a headwind to India's GDP growth. The extent of the downside will depend on the size of the penalties imposed," said Aditi Nayar, Chief Economist,
ICRA
said.
All in all, experts say the market will have to live with volatility and the hope that this pressure leads to a deal.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
27 minutes ago
- The Hindu
Army says no ceasefire violation along LoC
The Army on Tuesday (August 5, 2025) said there has been no ceasefire violation along the Line of Control (LoC) in Jammu and Kashmir. 'There have been some media and social media reports regarding ceasefire violation in Poonch region. It is clarified that there has been no ceasefire violation along the LoC. Please avoid spreading unverified information,' the Army said in a statement in New Delhi. Earlier, official sources in Jammu said the Pakistan Army had on Tuesday evening (August 5, 2025) indulged in 'unprovoked' firing on forward Indian posts along the LoC, prompting strong retaliation by the Indian Army. The exchange of small arms firing between the two sides continued for nearly 15 minutes in the Mankote sector but there was no immediate report of any casualties, the sources had said, adding it was the first instance of ceasefire violation since Operation Sindoor. Indian and Pakistani militaries engaged in intense clashes between May 7 and 10 after India launched missile strikes targeting terror infrastructure across the border under Operation Sindoor to avenge the Pahalgam terror attack.
Indian Express
27 minutes ago
- Indian Express
US to initially impose ‘small tariff' on pharma imports, Trump says
President Donald Trump said on Tuesday that the United States would initially place a 'small tariff' on pharmaceutical imports before hiking it to 150% within 18 months and eventually to 250% in an effort to boost domestic production. 'In one year, one and a half years maximum, it's going to go to 150% and then it's going to go to 250% because we want pharmaceuticals made in our country,' Trump told CNBC in an interview. He did not specify the initial tariff rate on pharmaceuticals. Trump said last month that pharmaceutical tariffs could reach as high as 200%. He said in February that sectoral tariffs on pharmaceuticals and semiconductor chips would start at '25% or higher,' rising substantially over the course of a year. Trump said on Tuesday that he plans to announce tariffs on semiconductors and chips in the 'next week or so,' but gave no further details. The United States has been conducting a national security review of the pharmaceutical sector, and the industry has been preparing for possible sector-specific tariffs. The administration has not announced when the results of that probe will be released. Several drugmakers have pledged multibillion-dollar investments in U.S. manufacturing as Trump threatens import tariffs, with AstraZeneca recently committing $50 billion to expand its American operations. PhRMA, the main lobbying group for the industry, did not immediately respond to a request for comment. A framework agreement between the United States and the EU sets out that tariffs on pharmaceuticals and semiconductors are currently zero, but if the United States raises tariffs following its import investigation, they will be capped at 15%.
Indian Express
27 minutes ago
- Indian Express
Trump says banks discriminate against his supporters while White House prepares order
US President Donald Trump on Tuesday said he believes that banks discriminate against him and his supporters, adding that Bank of America and JPMorgan Chase had previously refused to accept his deposits. 'They totally discriminate against, I think, me maybe even more, but they discriminate against many conservatives,' he told CNBC in an interview. 'I think the word might be Trump supporters more than conservatives.' Trump made the comments when asked about a report by the Wall Street Journal that said he planned to punish banks that discriminated against conservatives, but did not address the order specifically. The order instructs regulators to review banks for 'politicized or unlawful debanking' practices, according to a draft reviewed by Reuters. 'Well, they did discriminate,' Trump said of actions taken by JPMorgan Chase after his first term in office. 'I had hundreds of millions, I had many, many accounts loaded up with cash … and they told me, 'I'm sorry sir, we can't have you. You have 20 days to get out.'' Trump said, without providing evidence, that he believed that the banks' refusal to take his deposits indicated that the administration of former President Joe Biden had encouraged banking regulators to 'destroy Trump.' Trump said he subsequently tried to deposit funds with Bank of America and was also refused, and eventually split the cash among a number of smaller banks. 'The banks discriminated against me very badly,' he said. In a statement, JPMorgan did not address the president's specific claim that it had discriminated against him. 'We don't close accounts for political reasons, and we agree with President Trump that regulatory change is desperately needed,' JPMorgan said. 'We commend the White House for addressing this issue and look forward to working with them to get this right.' Bank of America also did not address Trump's specific claims in the CNBC interview. 'REPUTATIONAL RISK' ISSUE During President Joe Biden's administration, regulators could have asked the banks why they were providing banking services to Trump because of the 'reputational risk' issue, a source familiar with the matter said. Another source said that banks were under intense scrutiny and pressure with regards to what qualified as a reputational risk for banks and they needed to be careful due to Trump's legal entanglements. The source also added that at present JPMorgan continues to have a banking relationship with members of the Trump family that dates back to years ago and that they also bank a number of campaign accounts related to Trump. After President Trump took power, the Federal Reserve announced in June it was directing its supervisors to no longer consider 'reputational risk' when examining banks, scrapping a metric that had been a focus of industry complaints. The Wall Street Journal reported late Monday that the expected executive order would instruct regulators to investigate whether any financial institutions breach the Equal Credit Opportunity Act, antitrust laws or consumer financial protection laws by dropping customers for political reasons. It said the order could be signed as early as this week, authorizing monetary penalties, consent decrees or other disciplinary measures against violators. The White House had no immediate comment on the reported order. 'What the White House is doing is telling the banks not to hide behind regulations to deny loans or banking relationships,' said Wells Fargo bank analyst Mike Mayo. 'The banks can use their normal underwriting standards and deny services, but not blame regulators or use reputational risk as a justification.' Bank of America said it welcomed the Trump administration's efforts to provide regulatory clarity to banks. 'We've provided detailed proposals and will continue to work with the administration and Congress to improve the regulatory framework,' the bank said. Trump in January said the CEOs of JPMorgan Chase and Bank of America denied services to conservatives. At the time, the two banks denied making banking decisions based on politics. 'This seems to be rhetoric that will likely be forgotten by lunchtime,' said David Wagner, head of equities at Aptus Capital Advisors. 'I don't see any material impact on banks, as there are many other drivers that will ultimately presage performance for banks, such as deregulation.' JPMorgan and Bank of America shares both fell over 1%, in line with a decline for the broader S&P Bank index. Banks have consistently argued that any complaints about 'debanking' should be aimed at regulators, as they argue onerous rules and bank supervisors policing firms can discourage them from engaging in certain activities. 'The heart of the problem is regulatory overreach and supervisory discretion,' the Bank Policy Institute, an industry group, said in a statement. 'The banking agencies have already taken steps to address issues like reputational risk, and we're hopeful that any forthcoming executive order will reinforce this progress by directing regulators to confront the flawed regulatory framework that gave rise to these concerns in the first place.'
